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The three-body problem of therapy with induced
pluripotent stem cells
Jakub Tolar1* and John A McGrath2
Abstract
Regenerative medicine has a three-body problem:
alignment of the dynamics of the genome, stem cell
and patient. Focusing on the rare inherited fragile skin
disorder epidermolysis bullosa, three recent innovative
studies have used induced pluripotent stem cells and
gene correction, revertant mosaicism or genome
editing to advance the prospects of better cell-based
therapeutics to restore skin structure and function for
epidermolysis bullosa and potentially other inherited
diseases.
One of the dominant ambitions of medicine today is for
genes and cells to be used as medications. However, cells
and genes do not operate independently of their envir-
onment, but always in the context of the recipient. The
default of cellular transplantation is rejection, the innate
and adaptive immune system protecting the host body.
We can apply the key concepts of transplantation biol-
ogy, tested over 50 years of bone marrow transplants, to
the development of graftable induced pluripotent stem
cell (iPSC)-derived cells and tissues. Three recent publi-
cations [1-3] extend iPSC-based therapy initiatives in the
field of regenerative dermatology and exemplify a larger
challenge for any clinically meaningful medical approach:
the need to simultaneously engineer genes, capture cellu-
lar stemness and graft gene-corrected cells into individuals
with an inherited skin disease.
A shipwreck, not a butterfly
In the severe forms of epidermolysis bullosa (EB), a
group of skin fragility disorders with profound implica-
tions for physical and mental health, even slight friction
causes the layers of mucocutaneous membranes to slide
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apart and results in painful wounds that can resemble
severe burns. The most overwhelming of these skin con-
ditions are recessive dystrophic EB (RDEB) and junc-
tional EB (JEB), autosomal recessive disorders in which
the genes encoding major skin adhesion proteins do not
function properly, leading to severely diminished or ab-
sent gene expression. Patients with these disorders are
often called ‘butterfly children’ because of their delicate
and easily damaged skin, and the fact that many do not
survive into adulthood.
This disorder has an impact far beyond the skin, as
these individuals experience severe skin blistering, cor-
neal erosions, and mucosal wounds that can result in
malnutrition. EB is a horrible and frequently fatal disease
that wrecks any attempt at a normal life, both for the
sufferer and for the family. Despite the intense efforts of
medical scientists around the globe, there is currently no
cure. However, as the work from three teams discussed
herein demonstrates [1-3], scientists are working with
determination and creativity on a cure.
Furry test tubes
Murine models have proven tremendously useful in
studying the basic biology of human inherited skin dis-
eases and in preclinical modeling of potential thera-
peutic interventions. For RDEB, at least two murine
models exist, one with no expression of basement mem-
brane type VII collagen (C7) [4], and one with approxi-
mately 10% wild-type expression of C7 [5]. The groups
of Penninger and Bruckner-Tuderman [1] used the latter
model, and reprogrammed tail skin fibroblasts into
iPSCs that were used for therapy. To demonstrate the
feasibility of this iPSC-based therapy, mutant cells were
corrected, restoring the function of Col7a1. These cor-
rected iPSCs were then differentiated back into fibro-
blasts, and injected intradermally into mutant mice.
Expression of C7 increased over the first 8 weeks and
then declined to the baseline levels expected in this
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model of RDEB (corresponding with the decline of
donor cells to undetectable numbers over the same
period). Importantly, no obvious abnormal inflammatory
response, fibrosis or tumor formation (such as teratoma
derived from an errant iPSC, or squamous cell car-
cinoma (SCC) associated with the pathophysiology of
RDEB) was observed over the 18 weeks after therapy. To
demonstrate functionality of the new C7, the authors
tested the skin stability and observed it increased after
injection of corrected fibroblasts, but not after adminis-
tration of uncorrected mutant cells. This is a key obser-
vation, since previous work indicated that injection of
cells or just a cell-free solution can also increase expres-
sion of mutant C7 at the epidermal-dermal junction in
human RDEB subjects with hypomorphic COL7A1 mu-
tations [6] and improve wound healing, presumably in
part by changing a chronic wound into an acute one.
Rebooted skin cells
Equally important to advances in the clinical application
of iPSC therapy has been reprogramming keratinocytes,
the major cell type expressing C7 in normal skin, with
genetic reversion of the disease-causing mutations. Re-
vertant mosaicism occurs in some RDEB patients, pro-
viding a source of naturally gene-corrected skin cells.
Researchers have previously generated personalized iPSCs
and iPSC-derived skin cells from individuals with JEB [7],
RDEB [8] and mosaic RDEB [9]. Now Christiano and
colleagues [2] have used keratinocytes with a naturally oc-
curring reversion in the COL17A1 gene (encoding type
XVII collagen) from a healthy appearing skin patch of
an individual with JEB, reprogrammed them into iPSCs,
and differentiated them into keratinocytes with the cap-
acity to form skin-like organoids. These advances are
elegant and promising tools in future EB therapies, even
though three key challenges remain: the iPSCs were
generated with retroviral-mediated transgenesis, which
is unlikely to be acceptable in clinical trials; the skin-like
equivalents are not true skin grafts; and the graftable
keratinocytes have not yet been tested in a murine
model of EB.
Have a nice DNA
The brilliant approach represented by the work of Oro
and colleagues [3] is aimed at helping the majority of
people with EB who do not have clinically identifiable
mosaic cells (or in whom the gene reversion leads to
only partial restoration of collagen expression). They
propose gene correction of EB-causing mutations by
gene editing. In contrast to the predominant current
approach to gene therapy using viral vectors to deliver
the gene of interest to the genome (gene addition), gene
editing employs homology-driven repair to replace the
disease-causing mutation in situ, in principle leaving no
other footprint in the genome. This is important, as the
viral vectors used in the past led in several instances to
position effect after genomic insertion, activation of
proto-oncogenes, and cancer. Gene editing has been
used previously for correction of human RDEB muta-
tion in skin cells reprogrammed to iPSCs and differ-
entiated to keratinocytes [10], but in this work they
used highly recombinogenic adeno-associated virus to
mediate COL7A1 gene editing in RDEB fibroblasts, which
they could reprogram to pluripotency and differentiate
into keratinocytes. They have performed a thorough
analysis of expression profiles and off-target effects in
gene-edited cells and found no alterations with identifiable
genotoxicity.
Second skin is not enough
Many new questions arise as the boundaries of genome
and cellular engineering are explored. Firstly, it remains
to be determined whether iPSC-derived skin cells can be
induced to maintain long-lasting functionality, whether
they can be injected repeatedly without side effects, and
whether the extracellular matrix of EB skin can be modi-
fied to improve their therapeutic benefit. Secondly, the
corrective mechanisms underpinning revertant mosai-
cism are not yet clear. How many cells are needed for
clinically meaningful change in skin stability, and what is
the in vivo selection advantage, if any, of the reverted
cells? Finally, wounds in EB arise both inside and outside
the body, in varying severity and longevity, and at any
time. Using skin grafting for all the wounds may not be
feasible, especially given that the skin is the largest organ
of the body. Another difficulty is that EB is a systemic
disease with not just cutaneous wounds, but also muco-
sal wounds (esophagus and mouth), corneal abrasions,
and other organ malfunctions (such as chronic anemia,
kidney dysfunction and bone/dental disease). The risk of
SCC, typically aggressive, metastatic and lethal in severe
generalized forms of EB, will also likely persist as long as
any wounds remain.
Thus, the future of iPSC-based therapies in regenera-
tive dermatology is difficult to predict. The customized
gene-corrected cell is as yet only a tool. To realize its
potential clinical benefit, it must be transplanted into
the right environment and accepted, at least transiently.
Thus, although none of these three tasks, collagen gene
correction, skin cell culture and transplantation into in-
dividuals with EB, are singly sufficient, all are necessary
as researchers continue to pursue ways to relieve the ef-
fects of this disorder. In the future, these three separate
scientific foci must align and integrate to successfully
see translation of exciting science into the clinic. This
same approach is needed to grow confidence in applying
iPSCs to other genetic disorders and to regenerative
therapies in general.
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